WO2022264109 - MULTIVALENT INFLUENZA VACCINES
National phase entry:
Publication Number
WO/2022/264109
Publication Date
22.12.2022
International Application No.
PCT/IB2022/055655
International Filing Date
17.06.2022
Title **
[English]
MULTIVALENT INFLUENZA VACCINES
[French]
VACCINS MULTIVALENTS CONTRE LA GRIPPE
Applicants **
SANOFI
46 avenue de la Grande Armée
75017 Paris, FR
Inventors
ALEFANTIS, Timothy
c/o Sanofi, Patent Department
50 Binney Street
Cambridge, Massachusetts 02142, US
CHIVUKULA, Sudha
c/o Sanofi, Patent Department
50 Binney Street
Cambridge, Massachusetts 02142, US
Priority Data
63/212,523
18.06.2021
US
21315198.8
13.10.2021
EP
63/276,243
05.11.2021
US
PCT/US2021/058250
05.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3079 | |
| EPO | Filing, Examination | 18895 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 671 | |
| USA | Filing, Examination | 10560 |
Total: 33792 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are octavalent influenza vaccine compositions comprising eight mRNA, each mRNA comprising an open reading frame encoding a different influenza antigen. Also provided are lipid nanoparticles (LNPs) for delivering said mRNA.[French]
L'invention concerne des compositions de vaccins octovalents contre la grippe comprenant huit ARNm, chaque ARNm comprenant un cadre de lecture ouvert codant pour un antigène de la grippe différent. L'invention concerne également des nanoparticules lipidiques (LNP) destinées à administrer lesdits ARNm.